Member Info for Balerno2

Hi Ruck,

That would be another 3 years for the trial and more delays.

Hi TF, my point is that theee hasn’t been an RNS about validation. Which market based or PR people read or understand scientific journals?

At least Pl admitted pharmas we seeking more data. However continually asking for data can be a bottomless and demoralising pit. Sometimes the bull needs to be taken by the horn.

Yes don’t know about everyone else but I did expect and RNS about the poster presentation as it provides more validation of scib1. No publicity is bad publicity. I suppose this demonstrates that as technical RNSs often lead to price falls, so does the lack of an expected RNS.

So again we’re awaiting COMMERCIAL information. So when are Genmab going to make the announcement about progression of the first glymab?

Is this a portent of the new regime?

Got to start asking about our Business Devt Mgr?

Yes C7 top guy who has fought this disease for years and showed leadership here. Well remembered mate. Sorry we didn’t meet up.

I had expected him to be granted options but at the year end and a smaller amount. So the generosity is amazing and causes us to ask what did he promise by when? He’s 62, contacts and higher level experience than other incumbents. LD must also want to smell the roses.

So he drove a hard bargain and will do so on any deal. A good sign!

Given in April PL will be offered options and then will buy. Why do it before the option price is struck?

Also beware that PL will be granted options at this low price. What incentive does he have to counteract this before April/June?

Reminds me of when my firm got into cash flow problems cause the new DTI invoicing system had failed because of a consultant’s failure in implementation. HMRC were chasing payments too on tax and vat. A nightmare.

In this case you have to hang on but remember the vultures will be circling.

The darkest part of the night is before the dawn.

Yes that reinforced my earlier impression. A very positive character based upon data and the leadership skills shown so far. I suspect there will be more news before the middle of the year.

This should have an uptick now.

First time I’ve seen him speak and looks like he doesn’t take any nonsense with clear and systematic rationale given to questions. I wonder what deliverables he has in his contract?

Also I hope his appointment will be an end to the constant time slippages we have had over the years.

So I just asked apple ai through Siri to tell me what goals Sclp have. It then asked use ChatGPT. Did it reply? No it went dead.

Hi EE and Cleaner,

Yes we are all getting older. The timing of LD smelling the roses, l’Huillier on maybe a 3 year contract plus the loan notes extension till 2027?, plus major clinical results delivered by 2027 suggests that’s the new goal.

I hope that I last that long without having a personal cash call!

Sorry but big bucks bios with cash flow and household profile have the resources to influence the media to generate mRNA vaccine articles. Sclp has always been an outlier until other medium bio take a punt on a potential disruptor. That punt has started with Genmab but not at a level to mean real disruption. Given the conservative nature of clinicians and Pharma, we still have some time to go before recognition and our magic moment. At least 3 years given our new CEO contract and the outstanding loan notes. Hope I’m still here to benefit.

So what was the UC 6.4m trade at 16.27 followed by a sneaky 20 to push the closing up to 11.5p? A tidying up job or is this the portent for some real action SP wise?

So we’re running out of days by the end of the year to get the news about the trial progress of the first glymab licenced by Gemmab.

I thought that the condition you got the vaccine was that it has to be administered in the Donbass near the Russian front.

Anyway who would trust a vaccine like that? So Putin will say that he’s been using it and has nothing to do with his mental state.

Yes a good RNS which only delivers a decreasing trend of rises. It shows commercial ineptitude which the new ceo can ascribe to the previous incumbent LD. He can now build confidence and the SP but not before he gets his options.

Hi violin.,

I’ve always thought that inan’s £8 per share did include consolidation. The reason being that it has not been changed as the number of shares in issue has increased.

At long last!!!!!

At long last!!!!!